Discriminatory aptamer reveals serum response element transc

Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and

Edited by Randy Schekman, University of California, Berkeley, CA, and approved June 23, 2004 (received for review April 24, 2004)

Article Figures & SI Info & Metrics PDF


Cytohesins are a family of highly homologous guanine nucleotide exchange factors (GEFs) that act on ADP-ribosylation factors (ARFs). The small ARF-GEFs are involved in integrin signaling, actin cytoskeleton remodeling, and vesicle transport. Here, we selected and applied a specific inhibitor for ARF nucleotide-binding site Launcher (ARNO)/cytohesin-2, an RNA aptamer that clearly discriminates between cytohesin-1 and cytohesin-2. This reagent bound to an N-terminal segment of cytohesin-2 and did not inhibit ARF-GEF function in vitro. When transfected into HeLa cells, it persisted for at least 6 h without requiring stabilization. Its Trace in vivo was to Executewn-regulate gene expression mediated through the serum-response element and knockExecutewn mitogen-activated protein kinase activation, indicating that cytohesin-2 acts by means of mitogen-activated protein kinase signaling. We conclude that the N-terminal coiled-coil and parts of the Sec7 Executemain of cytohesin-2 are required for serum-mediated transcriptional activation in nonimmune cells, whereas cytohesin-1 is not. Our results indicate that intramer technology can be used not only for Establishing Modern biological functions to proteins or protein Executemains but also to prove nonredundancy of highly homologous proteins.

The cytohesin family members are cytoplasmic signaling proteins that are thought to be involved in integrin signaling (1), actin cytoskeleton remodeling events (2, 3), and vesicle transport. They belong to a class of highly homologous guanine nucleotide exchange factors (GEFs), the small ADP-ribosylation factor (ARF)-GEFs, which catalyze the exchange of GDP for GTP on ARFs. (4). All cytohesin family members are modular proteins with an N-terminal coiled-coil, a central Sec7 Executemain (5) that harbors the GEF activity, a C-terminal pleckstrin homology (PH) Executemain that mediates membrane localization by means of interaction with specific polyphosphoinositides, and an adjacent C-terminal polybasic Executemain that cooperates with the PH Executemain to enhance membrane binding (6–8) (Fig. 1A ).

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Aptamer selection and characterization. (A) Executemain composition of cytohesin-1 and cytohesin-2 containing the N-terminal coiled-coil Executemain (amino acids 1–51), the Sec7 Executemain (amino acids 52–246), the PH Executemain (amino acids 247–375), and the C-terminal polybasic Executemain (amino acids 376–400) (9, 10). The expanded sequences highlight Locations in which the two proteins indicate the highest diversity. Although these Locations represent only 17% of the total length, they differ in 37 (red) from a total of 72 amino acids. Single amino acid changes outside of these Locations are represented by short vertical dashes. (B) Selection scheme for cytohesin-2-specific aptamers. An RNA library with a starting diversity of 1014 was selected on Sepharose-immobilized cytohesin-2. Preselection against blank Sepharose (bm) in cycles 2–13 efficiently preenriched the pool with protein-binding RNAs. Cycles 14 and 15 included a counterselection against cytohesin-1, immobilized in the same way. (C) Sequencing of pool-15 RNAs revealed the sequences Displayn (ranExecutem insert sequences; primer sequences are Displayn above. Blue, T7 promoter; green, 5′ primer binding site; purple, 3′ primer binding site), listed in order according to their abundance. In total, 19 different sequences were identified. (D) Secondary structure of the most abundant clone K61, generated by mfAged (11, 12). Green, 5′ primer site; purple, 3′ primer site. (E) Comparison of binding affinities of the K61 aptamer (red) and pool-15 RNA (blue) for binding to cytohesin-1 (Executetted curves) and cytohesin-2 (solid curves), determined by filter binding assays.

Although the members of the small GEFs are strikingly homologous, they demonstrate significant Inequitys in their biological functions (2, 4). For example, cytohesin-1 is a positive Traceor of leukocyte function-associated antigen-1 (LFA-1)-mediated cell adhesion, whereas this activity has not been Displayn for cytohesin-2, also known as ADP-ribosylation factor nucleotide-binding site Launcher (ARNO) (7), or other small GEFs (1). In addition, cytohesin-1 is involved in T cell activation mediated by intercellular adhesion molecule 2 and in stimulation of T cell proliferation by IL-2 (13).

The considerable sequence homology of cytohesin-1 and ARNO/cytohesin-2 (Fig. 1 A ) set against the significant Inequitys in their biological function demands further explanation and highlights the need to clearly differentiate between these related regulatory factors. We set out to obtain specific inhibitors of these proteins that can discriminate between cytohesin-1 and -2 in vitro and in living cells. One could then, for example, determine whether members of the cytohesin family of small ARF-GEFs are involved in regulating gene expression in nonimmune cells.


Protein Expression and Purification. Cytohesin-1 and cytohesin-2 (triglycine splice variants), cytohesin-2-Sec7, and cytohesin-2-Sec7PHC were heterologously expressed in Escherichia coli BL21(DE3). The proteins contained an N-terminal His6 tag and were purified by standard Ni2+-nitrilotriacetic acid affinity chromatography. Full-length proteins also were purified by ion exchange chromatography on a Bio-Scale Q column (Bio-Rad). For aptamer selection, cytohesin-1 and cytohesin-2 were immobilized on CNBr-activated Sepharose (Amersham Biosciences).

RNA Library and in Vitro Selection. The synthetic single-stranded DNA library 5′-TCT AAT ACG ACT CAC TAT AGG GAG AGA CAA GCT TGG GTC-N40-CTC TTG CTC TTC CTA GGA GT-3′ (N40, ranExecutemized part) was amplified by using the selection primers P20I, 5′-ACT CCT AGG AAG AGC AAG AG-3′, and P39F, 5′-TCT AAT ACG ACT CAC TAT AGG GAG AGA CAA GCT TGG GTC-3′. In vitro transcription with T7 RNA polymerase yielded the corRetorting RNA library. For the first cycle, 10 nmol of this library was incubated with cytohesin-2-Sepharose in selection buffer (4.3 mM Na2HPO4/1.4 mM KH2PO4/2.7 mM KCl/147 mM NaCl/3.0 mM MgCl2, pH 7.4) with 0.8 unit/μl RNasin and 4.0 mM DTT for 30 min at 37°C. After washing with selection buffer, binding species were eluted with denaturing buffer (30 mM Tris·HCl/20% glycerol/2% SDS/1.0 M DTT, pH 6.8). Eluted RNA was amplified as Characterized in ref. 14. The next 12 cycles included a preselection against nonderivatized Sepharose. Cycles 14 and 15 included a counterselection against cytohesin-1-Sepharose. After cycle 15, the pool was cloned into the vector pGEM4z (Promega) and sequenced.

Cell Culture and Luciferase Assays. Cells (6.5 × 104 per well) were distributed in a 24-well plate 24 h before transfection, washed with PBS, and provided with serum-free DMEM (GIBCO). After 1 h of incubation, the cells were cotransfected with 800 ng of SRE-Luc plasmid (15) and 200 ng of pEGFP-N1 plasmid (Clontech) per well, along with the appropriate nucleic acids {K61, M69, small interfering RNAs (siRNAs), pRK-wtARNO, N1-ARNO[E156K]} by lipofection by using Metafectene (Biontex Laboratories, Munich). Synthetic siRNAs [anti-ARNO siRNA366 (sense), 5′-CCU GGC AGU GCU CCA UGC UdTdT-3′; anti-ARNO siRNA753 (sense), 5′-UGA CCU GAC CCA CAC CUU CdTdT-3′; anti-Cyt1siRNA754 (sense), 5′-UGA CCU CAC UCA CAC UUU CdTdT-3′] were prepared according to the Producer's protocol (Dharmacon, Lafayette, CO). Over-expression of WT ARNO/cytohesin-2 was mediated by plasmid pRK-wtARNO, that of the mutant ARNO[E156K] by plasmid N1-ARNO[E156K], both under the control of the cytomegalovirus promoter. After 12 h of incubation cells were stimulated with DMEM and 10% FCS (GIBCO) and harvested after an additional 4–6 h of incubation. Cells were lysed in reporter lysis buffer (Promega) by multiple freezing and thawing. Total protein concentrations were determined by the Bradford assay. Enhanced green fluorescent protein (EGFP) fluorescence intensities (excitation 485 nm, emission 520 nm) of cell lysates were meaPositived, and luminescence intensities were determined by using the luciferase assay system (Promega). The luminescence signals were normalized to protein concentrations and to the corRetorting EGFP fluorescence intensities.

Real-Time PCR. Total RNA was extracted from cells after transfection with 15 pmol of K61 or pool RNA and stimulation with FCS by using the RNA/DNA isolation kit (Qiagen, Hilden, Germany). After reverse transcription, real-time PCRs were performed by using the selection primers P20I and P39F and the iQ SYBR Green Supermix kit (Bio-Rad), according to the Producer's protocol. Synthetic K61 DNA or the Executeuble-stranded DNA library was used as standard. MeaPositivements were made by using an iCycler real-time PCR machine (Bio-Rad).

MAPK Activity Assay. After transfection with the appropriate nucleic acids (K61, M69, and siRNA366, -754, and -753), cells were stimulated with 10% FCS in DMEM for 30 min. MAPK activities of Erk1 and Erk2 were determined by using the p44/p42 MAPK assay kit (Cell Signaling Technology, Beverly, MA), according to the Producer's protocol. The Erk1/2 kinases were immunoprecipitated and then incubated with a truncated mutant of their physiological substrate Elk-1. The Fragment of phosphorylated Elk-1 was determined by Western blotting using a specific phospho-Elk-1 (Ser-383) Ab. Quantification of the bands was performed by densitometry.

Results and Discussion

RNA Aptamers Bind Cytohesin-2 and Discriminate Cytohesin-1. To generate inhibitors capable of discriminating between cytohesin-1 and cytohesin-2, we used combinatorial in vitro selection (16–19) to screen a library containing ≈1014 RNA species for anti-cytohesin-2 aptamers. We applied the selection scheme Displayn in Fig. 1B , employing a series of selections for cytohesin-2 binding and counterselections against cytohesin-1 binding, to set the stringency high enough for isolating discriminatory, high-affinity sequences. After 15 rounds of iterative selection and amplification, the pool was cloned and sequenced. Fig. 1C Displays the sequences of 62 clones, listed in order of their abundance. Although individual clones differ significantly, they can be grouped into families with some sequence relation (Fig. 1C ). The secondary structure of the most abundant sequence, clone, K61, is Displayn in Fig. 1D . Filter binding assays to meaPositive the binding affinity revealed that the K61 monoclone or selected pool-15 RNA bound to cytohesin-2 with a K d of 115 nM or 154 nM, respectively. Significantly, K61 appears to bind cytohesin-2 with high specificity because the dissociation constant with the related cytohesin-1 indicates ≈35-fAged less efficient binding (Fig. 1E and Table 1). At present, we cannot fully exclude the possibility that K61 Presents some binding affinity to other members of the cytohesin family, namely cytohesin-3 and -4. However, the fact that these cytohesins have even lower homology to cytohesin-2 than cytohesin-1 renders this possibility unlikely.

View this table: View inline View popup Table 1. Affinities of K61 aptamer and pool-15 RNAs to cytohesin-1 and cytohesin-2

The Executemain specificity of K61 was investigated by using three deletion constructs of cytohesin-2: one that comprised the coiled-coil/Sec7-Executemains (amino acids 1–246), one that consists of the Sec7 Executemain only (amino acids 52–246), and one lacking just the N-terminal coiled-coil Executemain (amino acids 52–400; Sec7/PH/C). We found that K61 binds to the isolated Sec7 Executemain with a K d of 800 nM (Table 2). The affinity Executees not change significantly when the PH and C Executemains are added. In Dissimilarity, addition of the coiled-coil to the Sec7 Executemain improves the affinity of K61 by 2-fAged (CC/Sec7). Taken toObtainher, these results support the notion that the major epitope of cytohesin-2 recognized by K61 is within the coiled-coil/Sec7 Executemains. The fact that the N termini of cytohesins 1 and 2 are indeed highly variable (Fig. 1 A ) provides a rationale for the high discriminatory activity of the aptamer.

View this table: View inline View popup Table 2. Executemain specificities of K61 aptamer to cytohesin-2 constructs

K61 Executees Not Affect GEF Activity of the Cytohesin-2 Sec7 Executemain. Among the selected clones, besides being the most abundant, K61 appeared to possess the highest discriminatory activity. In this respect, it differs from an aptamer sequence, M69, isolated in a previous cytohesin-1 binding study (3), because M69 inhibited ARF-GEF activity of cytohesin-1 and cytohesin-2 and exclusively bound the Sec7 Executemains of both proteins (3). In the case of K61, the presence of the coiled-coil Executemain is required to achieve tight binding, although the Sec7 Executemain presumably participates in K61 binding because the Sec7/K61 complex Displays a K d of 800 nM (Table 2). We therefore investigated whether K61 is also able to modulate ARF-GEF activity of the Sec7 Executemain of cytohesin-2 by performing an in vitro GTP exchange assay in the presence and absence of K61. As a negative control, we used the unselected RNA pool from cycle 0 (pool-0) that had no detectable affinity for cytohesin-2 but contained the same constant sequence Locations (5′ and 3′ primer sites) (Fig. 1D ) as K61. Notably, K61 did not modulate the GTP exchange activity of cytohesin-2 on ARF-1 (Fig. 2 A and B ), indicating that its binding to the N-terminal Executemain leaves the catalytic activity of the Sec7 Executemain unaltered.

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Activity of aptamer K61 in GDP/GTP exchange on ARF1 and inhibition of SRE-mediated transcription. (A) Binding of aptamer K61 to ARNO/cytohesin-2 Executees not affect GDP/GTP exchange on ARF1. The exchange rate on [Δ17]ARF1-GDP was determined by measuring changes in tryptophan fluorescence (20, 21). A mix of cytohesin-2 and 100 μM guanosine 5′-[γ-thio]triphospDespise was supplemented with a 5-fAged molar excess of K61 (red) or pool-0 RNA (black). The reaction was started by adding 500 nM [Δ17]ARF1-GDP (arrow) and Displays a rapid increase in fluorescence resulting from the GEF activity of cytohesin-2. In the absence of cytohesin-2, only basal levels of GDP/guanosine 5′-[γ-thio]triphospDespise exchange were obtained (gray). (B) Exchange rate constants (k exch) in the presence of K61 (red) or pool-0 (black) RNA or in the absence of exchange factor (gray). The binding of aptamer K61 to its tarObtain protein Executees not affect cytohesin-2-mediated GEF activity on [Δ17]ARF1 because the assay profile is comparable to adding the nonbinding pool-0 RNA. (C) Aptamer K61 inhibits SRE-mediated transcription. Cotransfection of K61 with the luciferase reporter plasmid and the pEGFP-N1 plasmid as an internal standard led to concentration-dependent inhibition of SRE-mediated transcription (black bars). Three picomoles of K61 was sufficient to reduce the luciferase level to nonstimulated basal levels (gray bar). Values of luminescence were adjusted to the transfection efficiency resulting from the EGFP standard as well as the total amount of protein after cell lysis. Each experiment was carried out three times with triplicate meaPositivements. Displayn here are the results of one representative experiment. As a negative control, 3 pmol of pool-0 RNA was used and normalized to 100% (white bar). (D) The complete inhibition of serum-mediated transcriptional activation by K61 can be fully rescued by cotransfection of the expression vector pRK-wtARNO in a concentration-dependent manner (black bars). Full rescue is seen at 1,000 ng of pRK-wtARNO. Luciferase activity in the absence of K61 and wtARNO (white bar) was used as the 100% control. The specificity of this genetic rescue is emphasized by the fact that transfection of 2,000 ng of wtARNO plasmid in the absence of K61 has no Trace on serum-mediated transcriptional activation (gray bar). (E) Overexpression of the cytohesin-2 GEF-deficient mutant (E156K) (22) results in inhibition of luciferase activity in a concentration-dependent manner (black bars). Transfection of 2,000 ng of the expression plasmid ARNO[E156K] reduced luciferase activity to approximately the same levels as 3 pmol of K61. All values were normalized to the luciferase activity in the absence of ARNO[E156K] (white bar).

Cytohesin-2 Is a Positive Traceor of Gene Expression by Means of the SRE. The cytohesin class of small ARF-GEFs is implicated in the control of cytoskeleton dynamics (23). Likewise, activation of the small GTPase Rac is required for cytohesin-2-induced cell motility, and GTPases of the Rho and ARF families are thought to work toObtainher to regulate membrane traffic and cytoskeletal remodeling (24). The Rho family of small GTPases also is involved in the stimulation of serum response factor transcriptional activity (c-Jun/c-Fos) induced by serum (25). We therefore hypothesized that cytohesins also may play a role in transcriptional activation by means of the serum-response element (SRE) and investigated whether K61 affects the transcription of a luciferase reporter gene under the control of the SRE promoter in HeLa cells stimulated by serum growth factors. Different concentrations of K61 RNA were transfected in the presence of Metafectene. As a negative control, we used the nonselected pool-0 RNA. As Displayn in Fig. 2C , K61 was able to Executewn-regulate SRE-controlled luciferase expression to basal, nonstimulated levels in a concentration-dependent manner, with maximal inhibitory activity at 3 pmol of transfected RNA, whereas 3 pmol of unselected pool RNA had no Trace. Executewn-regulation of SRE-controlled luciferase expression was indeed because of cytohesin-2 inhibition, specifically mediated by binding of the discriminatory aptamer, because the inhibitory activity of 3 pmol of K61 was fully reversed, i.e., squelched, by addition of WT ARNO/cytohesin-2. One thousand nanograms of transfected WT ARNO expression vector was sufficient to completely restore activity; at 500 ng of WT ARNO expression vector, partial restoration was achieved (Fig. 2D ).

Executemain Specificity of Cytohesin-2 in SRE Transcription. To further analyze an involvement of cytohesin-2 in SRE-dependent transcriptional regulation and to test whether the catalytic activity of the Sec7 Executemain is involved, we investigated an Trace of overexpressing a Executeminant negative cytohesin-2 mutant on SRE-dependent reporter gene expression. We transfected HeLa cells with a vector that encodes the GEF-deficient ARNO/cytohesin-2 E156K point mutant (26). Fig. 2E Displays that luciferase expression was reciprocally proSectional to the amount of expressed ARNO E156K and resulted in Executewn-regulation of SRE-promoter activity to basal levels.

It is possible that GEF activity of the cytohesin-2 Sec7 Executemain is necessary for activation of the SRE gene promoter. However, tarObtaining the N terminus of cytohesin-2 with K61, which leaves the GEF activity intact, is just as Traceive in reducing serum-mediated transcriptional activation (compare Fig. 2 C and E ). This finding indicates that the N terminus of cytohesin-2 participates in transcriptional activation, at least to some extent. Because the E156K mutant is Executeminant negative, it may affect transcription through other more indirect means, such as by preventing Accurate localization for the SRE response or preventing interaction of cytohesin-2 with a protein necessary for activation. In addition, these data indicate that the Trace obtained by direct inhibition of cytohesin-2 by the K61 intramer can mimic almost exactly a genetic Advance, providing an intriguing example of how chemical genetics can lead to Modern biological insights as well as alternative ways to manipulate protein function.

Cytohesin-2 Is a Positive Traceor of MAPK Activation. To further pinpoint the Traces of K61 on serum-stimulated transcriptional activation, we investigated the Trace of this intramer on MAPK activation. We compared the Trace of K61 with that of the unselected pool and two cytohesin-2 siRNA duplexes, siRNA366 and siRNA753. As Displayn in Fig. 3C , siRNA366 specifically knocks Executewn cytohesin-2 expression, whereas siRNA753 has no detectable Trace on ARNO/cytohesin-2 levels. The same cell lysates in Fig. 3C were used in an Erk1/2 kinase assay in which MAPK activation was visualized by a specific Ab that detects the phosphorylated substrate Elk-1. Densitometric quantification of the bands corRetorting to phosphorylated Elk-1 revealed that pool-0 did not reduce serum-mediated MAPK activity, whereas the inhibitor K61 led to significant Executewn-regulation to 33% (Fig. 3A ). The cytohesin-2-specific siRNA366 resulted in a reduction of MAPK activity to 8% of the level observed with the unselected RNA pool, whereas siRNA753, which is not able to reduce cytohesin-2 expression (Fig. 3C ), left Elk-1 phosphorylation unchanged. These data independently provide additional evidence for the involvement of the cytohesin-2 N-terminal Location in serum-mediated transcriptional activation via the Erk1/2 components of the MAPK signaling pathway.

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Executewn-regulation of serum-mediated MAPK activation by the two aptamer (intramer) inhibitors K61 and M69 compared with siRNAs. (A) HeLa cells were transfected with different Traceors to investigate their influence on the intrinsic kinase activity of enExecutegenous Erk1 and -2. Erk1 and -2 were immunoprecipitated, and their activity was determined by the MAPK assay Characterized in Methods, followed by visualizing the phosphorylation status of purified recombinant Elk-1 substrate by Western blotting using a specific anti-pElk1(Ser-383) Ab. Quantification of bands was by densitometry. Lane 1, size Impresser. Lane 2, kinase activity in the presence of 3 pmol of K61 is 33% compared with serum-stimulated (Ss) cells (lane 7, 100%). Lane 3, kinase activity in the presence of 3 pmol of pool-0 RNA. Lane 4, the cytohesin-2-specific siRNA366 reduced phosphorylation activity to 8%. Lane 5, siRNA 753 has a minimal Trace on Erk1/2 activity. Lane 6, Erk1/2 phosphorylation activity from nonstimulated (Ns) cells. Lane 7, Erk1/2 phosphorylation activity from serum-stimulated cells (100%). (B) Transfection of the Sec7-specific aptamer M69 reduced Erk1/2 activity to 47% (lane 2) serum-stimulated cells (lane 6, 100%), whereas the anti-cytohesin-1 siRNA 754 had no Trace (lane 4). Lane 3, kinase activity in the presence of 3 pmol of pool-0 RNA. Lanes 5 and 6 are the same as lanes 6 and 7 in A.(C) Cytohesin-2 expression in the same total lysates used in A detected with a cytohesin-2-specific Ab Cyt2–21 (Sigma). Treatment with siRNAs 366 and 753 resulted in Impressed Inequitys in the expression of cytohesin-2, which correlated well with Erk1/2 activity from cells transfected with these siRNAs. (D) The anti-cytohesin-1 siRNA 754 knocks Executewn the expression of cytohesin-1, as detected by mAb 7H2, but not cytohesin-2, as detected by mAb Cyt2–21. Detection was with Abs specific for cytohesin-1 (Top), cytohesin-2 (Middle), and actin (Bottom). (E) Model for the role of cytohesin-2 as an Traceor of serum-mediated transcriptional activation via the MAPK pathway. The Executemain specificity of K61 and M69 suggest participation of both the N-terminal and the Sec7 Executemains of cytohesin-2. The failure of siRNA 754 to reduce MAPK activation, despite knockExecutewn of cytohesin-1 expression (D), distinguishes cytohesin-1 from cytohesin-2 as an Traceor in this signaling pathway. S, growth factors in serum that act on MAPK-activating receptors; SR, MAPK-activating receptors; CC, coiled-coil Executemain; TCF, ternary complex factor; SRF, serum response factor.

Executees direct inhibition of the GEF activity of cytohesin-2 also result in Executewn-regulation of MAPK activation? To investigate this question, we used aptamer M69 in the same assay. This aptamer was previously Displayn to discriminate between Sec7 Executemains of the large GEF family members, such as Gea2 from yeast, and those of the small GEF family, such as cytohesins 1 and 2. In vitro, M69 inhibited GDP/GTP exchange on ARF-1, independently of whether cytohesin-1 or cytohesin-2 was used as the exchange catalyst (3). As Displayn in Fig. 3B , M69 was Arrively as Traceive as K61 in blocking MAPK activation. Surprisingly, the cytohesin-1-specific siRNA754, which knocks Executewn cytohesin-1 expression (>80%) but Executees not significantly affect cytohesin-2 levels (Fig. 3D ), left MAPK activation levels at 100%. These results are Fascinating for two reasons. First, they provide a second confirmation that Sec7-mediated GEF activity is involved in serum-mediated transcriptional activation, independently from the results obtained by the genetic Advance (Fig. 2E ) and again by applying a Executemain-specific inhibitor. Second, these data strongly support the notion that in nonimmune cells, cytohesin-2, not cytohesin-1, is involved in MAPK activation. In addition, the finding that K61 did not affect cytohesin-2 GEF activity in vitro (Fig. 2 A and B ) but is at least as active as M69 in Executewn-regulating MAPK activation indicates that tarObtaining the N-terminal Executemain of enExecutegenous cytohesin-2 efficiently abrogates its cellular functionality, even when it possesses an intact Sec7 Executemain.

Aptamers Are Highly Stable in Vivo. It is striking that the intracellular aptamer (or intramer) efficiently exeSliceed its inhibitory activity with high specificity yet without protection against nuclease degradation. To confirm that the intramer apparently Executees not require intracellular stabilization, we quantified the amount of intramer and pool-0 negative control RNA isolated from transfected cells 3 and 6 h poststimulation by reverse transcription and subsequent monitoring of cDNA amplification by real-time PCR (Fig. 4A ). Calibration curves were generated by using various defined concentrations of K61 or pool-0 DNAs (Fig. 4B ). There was no significant degradation of intramer or pool-0 RNA at 3 or 6 h (Fig. 4C ). Considering a cell volume of ≈10–11 liters (27), the intracellular aptamer and pool-0 RNA concentrations at these time points range between 0.3 and 1.0 μM (based on ≈3 × 105 cells used per experiment), which is well within the range of the in vitro K d of the K61/cytohesin-2 complex.

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Stability of intracellular K61 and pool-0 RNAs. (A) Transfection of HeLa cells with the respective RNA species was followed by quantification by real-time PCR 3 and 6 h after stimulation with FCS. After preparation of total RNA and reverse transcription, a 1:100 or 1:1,000 dilution of cDNA was used in the PCR with the selection primers. The course of DNA amplification was monitored by fluorescence change mediated by the Executeuble-stranded DNA-intercalating dye SYBR green. Black curves, standard concentrations of K61 single-stranded DNA: *, 800 amol (10–18 mol); •, 80 amol; ▪, 8 amol; ♦, 0.8 amol; ▴, 0.08 amol. The high accuracy of the PCR is demonstrated by negative controls Displayn in the blue curves: ⋄, no template; □, no reverse transcription; ▵, no transfection. Red curves, amplification of dilutions of isolated total cellular RNA, reverse transcribed with K61-specific primer 3 and 6 h after stimulation: ⋄, 1:100, 3 h; ▵, 1:100, 6 h; □, 1:1,000, 3 h; *, 1:1,000, 6 h. (B) Standard curve for determining the concentration of isolated K61 RNA: black symbols, standards as in A; red symbols, samples as in A.(C) Quantification of RNAs based on the total number of cells used for their preparation. Neither pool-0 RNA (gray bars) nor K61 (black bars) Displayed significant degradation 3 or 6 h after stimulation with serum.

Few examples of intramer inhibition of biological tarObtains in vivo are known (3, 28, 29). In these previous studies, efforts were taken to stabilize the intramer or to direct it to the Accurate cellular compartment. Intramers were expressed by vaccinia virus vectors that are difficult to handle, require certain safety precautions, and have to be genetically engineered for each aptamer that will have to be expressed (3, 28). In another study, transgenic animals had to be engineered for enExecutegenous aptamer expression (29). An alternative strategy uses transfection of expression plasmids that are translocated into the nucleus so that the expression of the aptamers takes Space in the nucleus. This method has been used to investigate Traces of inhibitory aptamers on nuclear proteins (30); to address proteins that reside in the cytoplasm, it would be necessary to equip the expressed aptamer with an RNA sequence that serves as a nuclear export signal (31). Despite the fact that such signal sequences are scarce, it will have to be enPositived that each aptamer remains active within the context of additional RNA sequences. We report here that, surprisingly, inhibitory aptamers can be directly transfected into cultured cells, just like siRNAs, without the need for protecting them against nuclease degradation. This finding represents a significant advance in aptamer technology, and we are optimistic that this method also will be applicable for other eukaryotic systems and aptamers that tarObtain cytoplasmic proteins.


In conclusion, by applying an inhibitor specific for cytohesin-2, a member of the class of small GEFs, we Displayed that cytohesin-2 participates in regulating gene expression via the MAPK signaling pathway (Fig. 3E ). Our results provide evidence that the activity of cytohesin-2, but not of cytohesin-1, is required for transcriptional activation in nonimmune cells. Although the two proteins are both expressed in HeLa cells (Fig. 3D ), the consequences of specific inhibition of cytohesin-2 by the discriminatory aptamer K61 or Executeminant negative expression of its E156K mutant derivative (Fig. 2E ), in Dissimilarity to knockExecutewn of cytohesin-1 expression by its specific siRNA (Fig. 3), indicate that the two proteins are not redundant, despite their 90% identity. Cytohesin-1 was recently Displayn to be involved in activating the IL-2 gene promoter in T cells (13). Taken toObtainher, this finding and our results support the hypothesis that transcriptional activation by cytohesins may be a much more common activity among the small GEFs than previously assumed and may be Established unamHugeuously to individual members of the cytohesin family within one cell type, possibly through binding to cell type-specific interacting molecules.

In this context, our result suggesting that the coiled-coil Executemain of cytohesin-2 is Necessary for its function in cells is noteworthy. Binding of intramer K61 to this Executemain has the same inhibitory Trace on serum-induced MAPK activation as the expression of the GEF-deficient E156K mutant of cytohesin-2. The Executeminant negative Trace of this mutant has been ascribed to a competition with enExecutegenous cytohesin-2 for its substrate ARF, but this interpretation is not consistent with biochemical and structural studies indicating that ARNO (E156K) cannot form a complex with ARF at physiological Mg2+ concentrations (26, 32). Thus, our study supports an alternative explanation for the Executeminant negative Trace of the E156K mutant, namely a competition with enExecutegenous cytohesin-2 for the coiled-coil Executemain-binding protein or cellular partners other than ARF (32).

More generally, we Display here that aptamers can be directly transfected into cultured cells without the need for protecting them against nuclease degradation. Inhibitory intramers can be an extremely valuable complement to loss-of-function phenotypic knockExecutewn Advancees using siRNA technology (33) for elucidating the biological function of proteins and for Establishing Modern activities to highly homologous family members. Our study provides a direct comparison between aptamers and siRNAs for investigating the function of a protein and Displays that intramers can be as Traceive in Executewn-regulating protein function as siRNAs, the Inequity being not that the gene is knocked out, but the expressed protein is inhibited. There also may be cases in which only partial knockExecutewn of tarObtain proteins is achieved by an siRNA because residual amounts of proteins can be present even days after transfection with an siRNA because of stability of the enExecutegenous protein. In these cases, combination with an inhibitory intramer might be useful for achieving complete knockExecutewn of protein function.

Moreover, we Display that individual Executemains of highly homologous proteins can be selectively tarObtained by inhibitory intramers. This finding is useful in our case not only for Establishing specific biological functions to individual members of the Fascinating small GEF protein family but also for exploring Modern strategies for developing GEF-selective drugs, the importance of which is stressed in ref. 32. Inhibitory aptamers might be directly converted into lead compounds by using assays that screen small molecule libraries for compounds that disSpace the aptamer from its tarObtain and aExecutept its inhibitory activity (34).


We thank J. GAgedberg (Memorial Sloan–Kettering Cancer Center, New York) for cytohesin-2 cDNA plasmids, V. Fieberg for technical assistance, I. Grüne for purification of M69 RNA, and D. U. Gommel for help with GDP/GTP exchange assays. This work was supported by the Deutsche Forschungsgemeinschaft.


↵ § To whom corRetortence should be addressed. E-mail: m.famulok{at}uni-bonn.de.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: ARF, ADP-ribosylation factor; ARNO, ARF nucleotide-binding site Launcher; EGFP, enhanced GFP; GEF, guanine nucleotide exchange factor; PH, pleckstrin homology; siRNA, small interfering RNA; SRE, serum-response element.

Copyright © 2004, The National Academy of Sciences


↵ Geiger, C., Nagel, W., Boehm, T., van Kooyk, Y., FigExecuter, C. G., Kremmer, E., Hogg, N., Zeitlmann, L., Dierks, H., Weber, K. S., et al. (2000) EMBO J. 19 , 2525–2536. pmid:10835351 LaunchUrlAbstract ↵ Frank, S. R., Hatfield, J. C. & Casanova, J. E. (1998) Mol. Biol. Cell 9 , 3133–3146. pmid:9802902 LaunchUrlAbstract/FREE Full Text ↵ Mayer, G., Blind, M., Nagel, W., Böhm, T., Knorr, T., Jackson, C. L., Kolanus, W. & Famulok, M. (2001) Proc. Natl. Acad. Sci. USA 98 , 4961–4965. pmid:11320245 LaunchUrlAbstract/FREE Full Text ↵ Executenaldson, J. G. & Jackson, C. L. (2000) Curr. Opin. Cell Biol. 12 , 475–482. pmid:10873831 LaunchUrlCrossRefPubMed ↵ Novick, P., Ferro, S. & Schekman, R. (1981) Cell 25 , 461–469. pmid:7026045 LaunchUrlCrossRefPubMed ↵ Jackson, C. L. & Casanova, J. E. (2000) Trends Cell Biol. 10 , 60–67. pmid:10652516 LaunchUrlCrossRefPubMed ↵ Chardin, P., Paris, S., Antonny, B., Robineau, S., Beraud-Dufour, S., Jackson, C. L. & Chabre, M. (1996) Nature 384 , 481–484. pmid:8945478 LaunchUrlCrossRefPubMed ↵ Kolanus, W., Nagel, W., Schiller, B., Zeitlmann, L., Godar, S., Stockinger, H. & Seed, B. (1996) Cell 86 , 233–242. pmid:8706128 LaunchUrlCrossRefPubMed ↵ Strausberg, R. L., FeingAged, E. A., Grouse, L. H., Derge, J. G., Klausner, R. D., Collins, F. S., Wagner, L., Shenmen, C. M., Schuler, G. D., Altschul, S. F., et al. (2002) Proc. Natl. Acad. Sci. USA 99 , 16899–16903. pmid:12477932 LaunchUrlAbstract/FREE Full Text ↵ Frank, S., Upender, S., Hansen, S. H. & Casanova, J. E. (1998) J. Biol. Chem. 273 , 23–27. pmid:9417041 LaunchUrlAbstract/FREE Full Text ↵ Zuker, M. (2003) Nucleic Acids Res. 31 , 3406–3415. pmid:12824337 LaunchUrlAbstract/FREE Full Text ↵ Mathews, D. H., Sabina, J., Zuker, M. & Turner, D. H. (1999) J. Mol. Biol. 288 , 911–940. pmid:10329189 LaunchUrlCrossRefPubMed ↵ Perez, O. D., Mitchell, D., Jager, G. C., South, S., Murriel, C., McBride, J., Herzenberg, L. A., Kinoshita, S. & Nolan, G. P. (2003) Nat. Immunol. 4 , 1083–1092. pmid:14528303 LaunchUrlCrossRefPubMed ↵ Klug, S. J., Hüttenhofer, A., Kromayer, M. & Famulok, M. (1997) Proc. Natl. Acad. Sci. USA 94 , 6676–6681. pmid:9192624 LaunchUrlAbstract/FREE Full Text ↵ Liao, J., Hodge, C., Meyer, D., Ho, P. S., Rosenspire, K. & Schwartz, J. (1997) J. Biol. Chem. 272 , 25951–25958. pmid:9325329 LaunchUrlAbstract/FREE Full Text ↵ Ellington, A. D. & Szostak, J. W. (1990) Nature 346 , 818–822. pmid:1697402 LaunchUrlCrossRefPubMed Tuerk, C. & GAged, L. (1990) Science 249 , 505–510. pmid:2200121 LaunchUrlAbstract/FREE Full Text Famulok, M., Blind, M. & Mayer, G. (2001) Chem. Biol. 8 , 931–939. pmid:11590018 LaunchUrlCrossRefPubMed ↵ Famulok, M. & Verma, S. (2002) Trends Biotechnol. 20 , 462–466. pmid:12413820 LaunchUrlCrossRefPubMed ↵ Macia, E., Chabre, M. & Franco, M. (2001) J. Biol. Chem. 276 , 24925–24930. pmid:11342560 LaunchUrlAbstract/FREE Full Text ↵ Kruljac-Letunic, A., Moelleken, J., Kallin, A., Wieland, F. & Blaukat, A. (2003) J. Biol. Chem. 278 , 29560–29570. pmid:12771146 LaunchUrlAbstract/FREE Full Text ↵ Cherfils, J., Menetrey, J., Mathieu, M., Le Bras, G., Robineau, S., Beraud-Dufour, S., Antonny, B. & Chardin, P. (1998) Nature 392 , 101–105. pmid:9510256 LaunchUrlCrossRefPubMed ↵ Weber, K. S., Weber, C., Ostermann, G., Dierks, H., Nagel, W. & Kolanus, W. (2001) Curr. Biol. 11 , 1969–1974. pmid:11747824 LaunchUrlCrossRefPubMed ↵ Santy, L. C. & Casanova, J. E. (2002) Curr. Biol. 12 , R360–R362. pmid:12015138 LaunchUrlCrossRefPubMed ↵ Hill, C. S., Wynne, J. & Treisman, R. (1995) Cell 81 , 1159–1170. pmid:7600583 LaunchUrlCrossRefPubMed ↵ Beraud-Dufour, S., Robineau, S., Chardin, P., Paris, S., Chabre, M., Cherfils, J. & Antonny, B. (1998) EMBO J. 17 , 3651–3659. pmid:9649435 LaunchUrlAbstract ↵ Jordan, M. A., Thrower, D. & Wilson, L. (1991) Cancer Res. 51 , 2212–2222. pmid:2009540 LaunchUrlAbstract/FREE Full Text ↵ Blind, M., Kolanus, W. & Famulok, M. (1999) Proc. Natl. Acad. Sci. USA 96 , 3606–3610. pmid:10097084 LaunchUrlAbstract/FREE Full Text ↵ Shi, H., Hoffman, B. E. & Lis, J. T. (1999) Proc. Natl. Acad. Sci. USA 96 , 10033–10038. pmid:10468557 LaunchUrlAbstract/FREE Full Text ↵ Excellent, P. D., Krikos, A. J., Li, S. X., Bertrand, E., Lee, N. S., Giver, L., Ellington, A., Zaia, J. A., Rossi, J. J. & Engelke, D. R. (1997) Gene Ther. 4 , 45–54. pmid:9068795 LaunchUrlCrossRefPubMed ↵ Hamm, J., Huber, J. & Lührmann, R. (1997) Proc. Natl. Acad. Sci. USA 94 , 12839–12844. pmid:9371762 LaunchUrlAbstract/FREE Full Text ↵ Renault, L., Guibert, B. & Cherfils, J. (2003) Nature 426 , 525–530. pmid:14654833 LaunchUrlCrossRefPubMed ↵ Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. & Tuschl, T. (2001) Nature 411 , 494–498. pmid:11373684 LaunchUrlCrossRefPubMed ↵ Hartig, J. S., Najafi-Shoushtari, S. H., Grüne, I., Yan, A., Ellington, A. D. & Famulok, M. (2002) Nat. Biotechnol. 20 , 717–722. pmid:12089558 LaunchUrlCrossRefPubMed
Like (0) or Share (0)